Somatostatin modulators and uses thereof

Inventors

Zhao, Jian • ZHU, Yunfei • Wang, Shimiao • Han, Sangdon • Kim, Sun Hee

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11028068-B2

Patent

Publication Date

2021-06-08

Expiration Date


Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Core Innovation

The disclosure relates to non-peptidyl compounds having the structure of Formula (I), including quinoline-4-carboxamides and 1,5-naphthyridine-4-carboxamides with varied aryl or heteroaryl substituents and amine-containing side chains. These compounds, along with their pharmaceutically acceptable salts, solvates, diastereomeric mixtures, and enantiomers, modulate somatostatin receptors such as SSTR2. The claimed structures provide potent inhibitors of hormone secretion and serve as alternatives to peptide analogs.

The disclosure also encompasses an enumerated collection of specified quinoline-4-carboxamide and 1,5-naphthyridine-4-carboxamide analogs and pharmaceutical compositions formulated for potential oral administration. Exemplified compounds show reported SSTR2 activity in cAMP assays, with many displaying EC50 values below 100 nM for treating acromegaly or neuroendocrine tumors. Because background and summary sections are omitted from the supplied content, the specific technical problem being solved is not explicitly described in patent.

Claims Coverage

The provided claim information identifies two inventive features across two independent claims covering a Formula (I) compound genus and an enumerated collection of individual compounds.

Compounds of formula (I)

A compound having the structure of Formula (I), or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomer thereof, defining alternatives for cyclic ring groups, nitrogen-containing rings, substituents, and structural variables.

Specified quinoline-4-carboxamide and 1,5-naphthyridine-4-carboxamide compounds

An enumerated collection of specifically recited quinoline-4-carboxamide and 1,5-naphthyridine-4-carboxamide compounds having varied aryl or heteroaryl substituents and amine-containing side chains, or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomer thereof.

The independent claims cover the broad Formula (I) compound genus and a separately specified collection of quinoline-4-carboxamide and 1,5-naphthyridine-4-carboxamide compounds, including their stated pharmaceutically acceptable forms.

Stated Advantages

The compounds are presented as potent inhibitors of hormone secretion.

The non-peptidyl compounds are presented as alternatives to peptide analogs.

Potential oral administration is identified.

Documented Applications

A pharmaceutical composition comprising a claimed compound or a specified form thereof and at least one pharmaceutically acceptable excipient.

Treatment of acromegaly, neuroendocrine tumors, or combinations thereof in a mammal by administering a claimed compound to modulate SSTR2 activity.

Somatostatin-receptor modulation for other endocrine, ophthalmic, neurologic, respiratory, inflammatory, and cancer-related conditions.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.